Medtronic Announces $0.71 Dividend for Q2 FY2026, 48th Consecutive Year of Annual Dividend Increase.
ByAinvest
Friday, Aug 15, 2025 11:23 pm ET1min read
MDT--
Despite recent challenges, including a 33% decline in stock value since mid-2021, Medtronic remains focused on improving overall profitability and innovation. The company plans to spin off its diabetes business next year, which is expected to be accretive to earnings and free up capital for research and development or potential acquisitions [2].
Investors should note that Medtronic's business and stock performance may not improve overnight. The company is working on new product launches and addressing the challenges of regulatory approval and product development. However, the dividend yield currently stands at around 3.1%, historically high for the stock and well above the S&P 500 index's 1.2% yield [3].
Medtronic's recent CE Mark approval to expand the indications for its MiniMed 780G automated insulin delivery system across Europe further highlights its commitment to innovation and improving patient care. The approval now includes individuals as young as 2 years old, pregnant women, and people with type 2 insulin-requiring diabetes [4].
References:
[1] https://www.aol.com/3-things-know-buy-medtronic-100000838.html
[2] https://www.prnewswire.com/news-releases/medtronic-announces-cash-dividend-for-second-quarter-of-fiscal-year-2026-302530564.html
[3] https://za.investing.com/news/company-news/medtronic-declares-071-quarterly-dividend-for-fiscal-2026-93CH-3841407
[4] https://www.prnewswire.com/news-releases/medtronic-announces-cash-dividend-for-second-quarter-of-fiscal-year-2026-302530564.html
Medtronic has announced a quarterly cash dividend of $0.71 per ordinary share for Q2 FY2026, payable on October 17, 2025, to shareholders recorded by September 26, 2025. This marks the company's 48th consecutive year of increasing its annual dividend, solidifying its position as a member of the S&P 500 Dividend Aristocrats index.
Medtronic plc (NYSE: MDT) has announced a quarterly cash dividend of $0.71 per ordinary share for the second quarter of fiscal year 2026, payable on October 17, 2025, to shareholders of record at the close of business on September 26, 2025. This dividend is consistent with the company's May 2025 announcement of a dividend increase and marks the 48th consecutive year of increasing its annual dividend. This consistent dividend growth underscores Medtronic's commitment to rewarding shareholders and highlights its strong financial health [1].Despite recent challenges, including a 33% decline in stock value since mid-2021, Medtronic remains focused on improving overall profitability and innovation. The company plans to spin off its diabetes business next year, which is expected to be accretive to earnings and free up capital for research and development or potential acquisitions [2].
Investors should note that Medtronic's business and stock performance may not improve overnight. The company is working on new product launches and addressing the challenges of regulatory approval and product development. However, the dividend yield currently stands at around 3.1%, historically high for the stock and well above the S&P 500 index's 1.2% yield [3].
Medtronic's recent CE Mark approval to expand the indications for its MiniMed 780G automated insulin delivery system across Europe further highlights its commitment to innovation and improving patient care. The approval now includes individuals as young as 2 years old, pregnant women, and people with type 2 insulin-requiring diabetes [4].
References:
[1] https://www.aol.com/3-things-know-buy-medtronic-100000838.html
[2] https://www.prnewswire.com/news-releases/medtronic-announces-cash-dividend-for-second-quarter-of-fiscal-year-2026-302530564.html
[3] https://za.investing.com/news/company-news/medtronic-declares-071-quarterly-dividend-for-fiscal-2026-93CH-3841407
[4] https://www.prnewswire.com/news-releases/medtronic-announces-cash-dividend-for-second-quarter-of-fiscal-year-2026-302530564.html

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet